NCT02992964 - Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

November 20, 2023

Study Completion Date

November 20, 2023

Conditions

Refractory or Recurrent Hypermutated MalignanciesBiallelic Mismatch Repair Deficiency (bMMRD) Positive Patients

Interventions

DRUG

Nivolumab

Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 \[IgG4\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor.

Trial Locations (10)

19104

Children's Hospital of Philadelphia, Philadelphia

64239

Tel Aviv Sourasky Medical Centre, Tel Aviv

94800

Institut Gustave Roussy, Villejuif

02215

Dana-Farber Cancer Institute, Boston

Unknown

The Children's Hospital at Westmead, Westmead

Queensland Children's Hospital, South Brisbane

Women's and Children's Hospital, North Adelaide

Children's & Women's Health Centre of British Columbia, Vancouver

Centre Leon Berard, Lyon

M5G 1X8

The Hospital for Sick Children, Toronto